**Table S1**: Clinical testing results and demographic information for study cohort.

| Participant | Age (years) | Bleeding Disorder Diagnosis | Secondary diagnoses | VWF Activity (U/mL) | VWF Antigen (U/mL) | Factor VIII Activity (U/mL) | Hemoglobin (g/dL) | Platelet count (K/cu mm) | Platelet Aggregation Results | PFA |
|-------------|-------------|-----------------------------|---------------------|--------------------|-------------------|-----------------------------|----------------|--------------------------|-----------------------------|-----|
| 1           | 14          | No clinically-identifiable BD; lost to follow up | Vitamin D deficiency | 1.12               | 0.59              | 1.46                        | 13.5           | 265                      | Not done                     | Normal |
| 2           | 16          | Hyper-mobile EDS            | Iron deficiency anemia | 1.15               | 0.82              | 1.72                        | 11.4           | 295                      | Not done                     | Normal |
| 3           | 18          | BD, NOS                     | Iron deficiency anemia | 0.95               | 1.05              | 1.17                        | 13.6           | 306                      | Normal                       | Not done |
| 4           | 15          | No clinically-identifiable BD | Iron deficiency, ovarian cyst | 0.82               | 0.66              | 1.38                        | 12.6           | 298                      | Not done                     | Normal |
| 5           | 17          | QPD and thrombocytopenia*    | Thyroid nodule       | 1.42               | 1.27              | 2.02                        | 14.2           | 77                       | Normal                       | Not done |
| 6           | 17          | QPD                         | Low VWF, iron deficiency anemia | 0.45               | 0.45              | 1.26                        | 11.9           | 513                      | Impaired response to ADP 1:5, epinephrine 1:10 and 1:100 Epinephrine only prolonged | Normal |
| 7           | 14          | Hyper-mobile EDS            | Low VWF              | 0.43               | 0.38              | 0.87                        | 13.4           | 298                      | Not done                     | Normal |
| 8           | 15          | No clinically-identifiable BD | Iron deficiency anemia | 0.8                | 0.95              | 1.2                         | 13.8           | 302                      | Normal                       | Normal |
| 9           | 15          | Type 1 VWD                  | Iron deficiency anemia | 0.19               | 0.21              | 0.48                        | 11.5           | 331                      | ADP only prolonged           | Normal |
| 10          | 17          | Low VWF                     | None                 | 0.36               | 0.45              | 0.87                        | 13.3           | 258                      | Not done                     | Not done |
| 11          | 17          | No clinically-identifiable BD | None                 | 0.76               | 0.66              | 1.32                        | 14.9           | 301                      | Normal                       | Normal |
| 12          | 13          | No clinically-identifiable BD | Iron deficiency anemia | 0.84               | 0.77              | 1.52                        | 9.6            | 438                      | Not done                     | Normal |
| 13          | 14          | No clinically-identifiable BD | Iron deficiency anemia | 0.7                | 0.58              | 0.95                        | 12.8           | 253                      | Not done                     | Normal |
| 14          | 16          | QPD                         | Iron deficiency anemia | 1.44               | 1.14              | 1.44                        | 12.5           | 217                      | Impaired response to ADP 1:5, epinephrine 1:10 and 1:100 ADP and epinephrine prolonged | Normal |
| 15          | 14          | No clinically-identifiable BD | Iron deficiency anemia | 0.62               | 0.63              | 1.29                        | 11.6           | 376                      | Not done                     | Normal |

*Platelet-mapping thromboelastography demonstrated a defect in response to ADP. Bleeding symptoms persisted despite improvement of platelet count with steroid administration in this participant.*